The Archive · 32,142 records

Source documents — page 48 of 129

Source documents, page 48 of 129: records 11,751–12,000 of 32,142, titles F.

Browse by source, program, docket, document type or year.

Records 11,751–12,000 of 32,142

F

Form 4: Emergent BioSolutions Inc. (EBS), Lindahl Richard S, transaction 02/28/2022Emergent BioSolutions Form 4: LINDAHL RICHARD S, EVP, Chief Financial Officer, was…
Form 4: Emergent BioSolutions Inc. (EBS), Lindahl Richard S, transaction 05/08/2021LINDAHL RICHARD S, Emergent BioSolutions EVP, Chief Financial Officer, had 1,054 shares…
Form 4: Emergent BioSolutions Inc. (EBS), Lindahl Richard S, transaction 11/15/2021Emergent BioSolutions EVP, Chief Financial Officer LINDAHL RICHARD S bought 3,000 shares…
Form 4: Emergent BioSolutions Inc. (EBS), Richard Ronald, transaction 05/20/2021Emergent BioSolutions Form 4 for director Richard Ronald: 5,027 restricted stock units…
Form 4: Emergent BioSolutions Inc. (EBS), Richard Ronald, transaction 05/26/2022Emergent BioSolutions director Richard Ronald reports 8,446 restricted stock units…
Form 4: Emergent BioSolutions Inc. (EBS), Richard Ronald, transaction 08/07/2020Emergent BioSolutions Inc. Form 4, August 7, 2020: director Richard Ronald sold 6,297…
Form 4: Emergent BioSolutions Inc. (EBS), Richard Ronald, transaction 11/25/2022Emergent BioSolutions director Richard Ronald sold 1,912 shares at $11.94 on 11/25/2022…
Form 4: Emergent BioSolutions Inc. (EBS), Saran Atul, transaction 02/09/2021Emergent BioSolutions Inc. Form 4, February 9, 2021: SARAN ATUL received 2,656 PSU…
Form 4: Emergent BioSolutions Inc. (EBS), Saran Atul, transaction 02/22/2022Form 4: SARAN ATUL, Emergent BioSolutions EVP, Corp Dev, GC & Secretary, got 1,836 PSUs…
Form 4: Emergent BioSolutions Inc. (EBS), Saran Atul, transaction 02/23/2022SARAN ATUL, Emergent BioSolutions EVP, Corp Dev, GC & Secretary, reports 442 and 857…
Form 4: Emergent BioSolutions Inc. (EBS), Saran Atul, transaction 02/24/2021Emergent BioSolutions Inc. Form 4, February 24, 2021: SARAN ATUL received 3,744…
Form 4: Emergent BioSolutions Inc. (EBS), Saran Atul, transaction 02/28/2022SARAN ATUL, Emergent BioSolutions EVP, Chief Strat & Dev Officer, reports 31,417…
Form 4: Emergent BioSolutions Inc. (EBS), Saran Atul, transaction 08/07/2020Emergent BioSolutions Inc. Form 4, August 7, 2020: SARAN ATUL (EVP, Corp Dev, GC &…
Form 4: Emergent BioSolutions Inc. (EBS), Smith Karen L., transaction 02/24/2021Emergent BioSolutions Inc. Form 4: Smith Karen L., EVP, Chief Medical Officer, received…
Form 4: Emergent BioSolutions Inc. (EBS), Strei Katherine, transaction 02/09/2021Emergent BioSolutions Inc. Form 4: Strei Katherine (EVP, Chief HR Officer) received 2,014…
Form 4: Emergent BioSolutions Inc. (EBS), Strei Katherine, transaction 02/22/2022Emergent BioSolutions Form 4: Strei Katherine received 1,258 more performance stock units…
Form 4: Emergent BioSolutions Inc. (EBS), Strei Katherine, transaction 02/23/2022Emergent BioSolutions Form 4 for EVP, Chief HR Officer Strei Katherine: 344 and 590…
Form 4: Emergent BioSolutions Inc. (EBS), Strei Katherine, transaction 02/24/2021Emergent BioSolutions Inc. Form 4: Strei Katherine received 2,674 restricted stock units,…
Form 4: Emergent BioSolutions Inc. (EBS), Strei Katherine, transaction 02/28/2022Emergent BioSolutions Form 4: Strei Katherine, EVP, Chief HR Officer, received 24,167…
Form 4: Emergent BioSolutions Inc. (EBS), Sullivan Louis W, transaction 05/20/2021SULLIVAN LOUIS W, Emergent BioSolutions director, acquired 5,027 restricted stock units…
Form 4: Emergent BioSolutions Inc. (EBS), Sullivan Louis W, transaction 05/26/2022SULLIVAN LOUIS W, an Emergent BioSolutions director, acquired 8,446 restricted stock…
Form 4: Emergent BioSolutions Inc. (EBS), Sullivan Louis W, transaction 09/16/2020Emergent BioSolutions Inc. Form 4, September 16, 2020: director SULLIVAN LOUIS W gave…
Form 4: Emergent BioSolutions Inc. (EBS), White Marvin L, transaction 05/20/2021White Marvin L, an Emergent BioSolutions director, reports a 5,027-unit restricted stock…
Form 4: Emergent BioSolutions Inc. (EBS), White Marvin L, transaction 05/26/2022Form 4: White Marvin L, director of Emergent BioSolutions, was granted 8,446 restricted…
Form 4: Emergent BioSolutions Inc. (EBS), Zoon Kathryn C, transaction 05/20/2021Emergent BioSolutions Form 4: director Zoon Kathryn C was awarded 5,027 restricted stock…
Form 4: Emergent BioSolutions Inc. (EBS), Zoon Kathryn C, transaction 05/24/2022Emergent BioSolutions director Zoon Kathryn C sold 1,996 shares at $35.53 on 05/24/2022…
Form 4: Emergent BioSolutions Inc. (EBS), Zoon Kathryn C, transaction 05/25/2021Emergent BioSolutions director Zoon Kathryn C sold 3,139 shares on 05/25/2021 at a $56.48…
Form 4: Emergent BioSolutions Inc. (EBS), Zoon Kathryn C, transaction 05/26/2022Emergent BioSolutions Form 4: director Zoon Kathryn C received 8,446 restricted stock…
Form 4: Emergent BioSolutions Inc. (EBS), Zoon Kathryn C, transaction 06/09/2022Emergent BioSolutions director Zoon Kathryn C sold 1,173 shares at $31.52 on 06/09/2022,…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 01/04/2021INOVIO PHARMACEUTICALS (INO) director Simon X. Benito Form 4: 2,750 option shares…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 02/16/2021Form 4 for INOVIO PHARMACEUTICALS (INO) director Simon X. Benito: 2,000 option shares…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 03/16/2021Form 4: INOVIO PHARMACEUTICALS (INO) director Simon X. Benito exercised and sold 2,000…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 04/16/2021INOVIO PHARMACEUTICALS (INO) Form 4, director Simon X. Benito: 2,000 option shares…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 05/13/2021INOVIO PHARMACEUTICALS (INO) Form 4, director Simon X. Benito: director grants, 8,700…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Dansey Roger D, transaction 05/13/2021INOVIO PHARMACEUTICALS (INO) director Roger Dansey Form 4: 54,000 options at $6.23 and…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 02/26/2021Form 4: INOVIO PHARMACEUTICALS (INO) Chief Scientific Officer Laurent Humeau granted…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 03/05/2021INOVIO PHARMACEUTICALS (INO) Form 4, Chief Scientific Officer Laurent Humeau: RSUs…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 03/11/2021Form 4 for INOVIO PHARMACEUTICALS (INO) Chief Scientific Officer Laurent Humeau: 59,737…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 08/10/2020Form 4: INOVIO PHARMACEUTICALS (INO) Chief Scientific Officer Laurent Humeau sold 19,467…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 11/10/2020INOVIO PHARMACEUTICALS (INO) Form 4, Chief Scientific Officer Laurent Humeau: 19,466…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 01/15/2021Form 4 for INOVIO PHARMACEUTICALS (INO) CFO Peter Kies: 30,000 option shares exercised at…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 02/26/2021Form 4 for INOVIO PHARMACEUTICALS (INO) CFO Peter Kies: 67,633 RSUs and an option on…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 03/05/2021Form 4: INOVIO PHARMACEUTICALS (INO) CFO Peter Kies, RSU vestings 03/05/2021 and…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 03/11/2021INOVIO PHARMACEUTICALS (INO) CFO Peter Kies Form 4: 59,737 RSUs settled 03/11/2021;…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 04/21/2021INOVIO PHARMACEUTICALS (INO) CFO Peter Kies Form 4: 10,000 shares sold 04/21/2021 at…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 12/15/2020INOVIO PHARMACEUTICALS (INO) CFO Peter Kies Form 4: options on 8,750 and 11,250 shares…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 02/01/2021INOVIO PHARMACEUTICALS (INO) Form 4, Jong Joseph Kim: 100,000 shares sold 02/01/2021;…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 02/26/2021INOVIO PHARMACEUTICALS (INO) Form 4, Jong Joseph Kim: 319,800 options at $11.1 and…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 03/05/2021Form 4 for INOVIO PHARMACEUTICALS (INO), Jong Joseph Kim: 120,100 and 63,700 RSUs…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 03/11/2021Form 4: INOVIO PHARMACEUTICALS (INO), Jong Joseph Kim, 139,387 RSUs settled 03/11/2021;…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 12/29/2020Form 4, INOVIO PHARMACEUTICALS (INO): Jong Joseph Kim reports a 10,000-share charitable…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Miller Ann Calby, transaction 03/21/2021INOVIO PHARMACEUTICALS (INO) director Ann C. Miller Form 4: 4,274 restricted stock units…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 01/27/2021INOVIO PHARMACEUTICALS (INO) Form 4, Chief Operating Officer Jacqueline E. Shea: option…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 02/01/2021Form 4: INOVIO PHARMACEUTICALS (INO) Chief Operating Officer Jacqueline E. Shea exercised…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 02/26/2021INOVIO PHARMACEUTICALS (INO) Form 4, Chief Operating Officer Jacqueline E. Shea: 104,833…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 03/11/2021INOVIO PHARMACEUTICALS (INO) Form 4, Chief Operating Officer Jacqueline E. Shea: 59,737…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 03/25/2021Form 4 for INOVIO PHARMACEUTICALS (INO) Chief Operating Officer Jacqueline E. Shea:…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Shepard Jay, transaction 01/15/2021Form 4: INOVIO PHARMACEUTICALS (INO) director Jay Shepard received 4,274 shares from…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Shepard Jay, transaction 05/13/2021INOVIO PHARMACEUTICALS (INO) director Jay P. Shepard Form 4: 27,000 options, 18,000 RSUs…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 02/26/2021INOVIO PHARMACEUTICALS (INO) director David B. Weiner Form 4: 60,000 options at $11.1 and…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 03/05/2021INOVIO PHARMACEUTICALS (INO) director David B. Weiner Form 4: RSU vestings and…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 03/11/2021INOVIO PHARMACEUTICALS (INO) director David B. Weiner Form 4: 11,667 restricted stock…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 04/21/2021Form 4: INOVIO PHARMACEUTICALS (INO) director David B. Weiner, 22,500 option shares…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 05/13/2021Form 4 for INOVIO PHARMACEUTICALS (INO) director David B. Weiner: grants on 05/13/2021,…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 12/15/2020Form 4: INOVIO PHARMACEUTICALS (INO) director David B. Weiner exercised and sold 17,500…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Yarno Wendy L, transaction 05/13/2021Form 4: INOVIO PHARMACEUTICALS (INO) director Wendy Yarno, 27,000 options and 18,000 RSUs…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Yarno Wendy L, transaction 12/05/2020Form 4 for INOVIO PHARMACEUTICALS (INO) director Wendy Yarno: 4,090 restricted stock…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Zoth Lota S., transaction 01/03/2021Form 4 for INOVIO PHARMACEUTICALS (INO) director Lota S. Zoth: 4,090 RSUs vested…
Form 4: Inovio Pharmaceuticals, Inc. (INO), Zoth Lota S., transaction 05/13/2021Form 4: INOVIO PHARMACEUTICALS (INO) director Lota S. Zoth, director grants, 8,700 RSUs…
Form 4: Lucira Health, Inc. (LHDX), Allen Anthony Joseph, transaction 03/03/2023Lucira Health, Inc. [LHDX] Form 4 for Anthony Joseph Allen: 8,405 common shares sold on…
Form 4: Lucira Health, Inc. (LHDX), Allen Anthony Joseph, transaction 09/30/2021Form 4: Lucira Health (LHDX) Chief Operations Officer Anthony Joseph Allen granted…
Form 4: Lucira Health, Inc. (LHDX), Collins Kevin Walter, transaction 03/03/2023Lucira Health, Inc. [LHDX] Form 4: Kevin Walter Collins reports 30,102 shares sold…
Form 4: Lucira Health, Inc. (LHDX), Collins Kevin Walter, transaction 05/27/2022Lucira Health, Inc. [LHDX] Form 4: Kevin Walter Collins, Chief Revenue Officer, reports…
Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 02/04/2021Lucira Health (LHDX) Form 4: Erik T. Engelson granted an option on 173,937 shares at $17…
Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 02/09/2021Lucira Health (LHDX) Form 4: Erik T. Engelson's 23,282 Series C preferred shares…
Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 03/03/2023Lucira Health, Inc. [LHDX] Form 4: Erik T. Engelson exercised an option for 574,666…
Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 03/15/2022Form 4 for Lucira Health, Inc. [LHDX]: Erik T. Engelson, President and Chief Executive,…
Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 06/16/2022Form 4 for Lucira Health, Inc. [LHDX]: Erik T. Engelson reports 10,000 common shares on…
Form 4: Lucira Health, Inc. (LHDX), Gardiner Sandra A., transaction 06/01/2022Form 4 for Lucira Health, Inc. [LHDX]: Sandra A. Gardiner, a Director, reports a…
Form 4: Lucira Health, Inc. (LHDX), George Dan, transaction 02/04/2021Form 4: Lucira Health (LHDX) CFO and Treasurer Daniel George, option on 39,062 shares at…
Form 4: Lucira Health, Inc. (LHDX), George Dan, transaction 02/09/2021Form 4: Lucira Health (LHDX) CFO Daniel George converted 10,725 Series B and 13,288…
Form 4: Lucira Health, Inc. (LHDX), George Dan, transaction 06/18/2021Form 4: Lucira Health (LHDX) CFO and Treasurer Daniel George awarded 15,000 RSU shares on…
Form 4: Lucira Health, Inc. (LHDX), George Dan, transaction 06/18/2022Form 4 for Lucira Health, Inc. [LHDX]: Dan George, CFO and Treasurer, reports 1,321…
Form 4: Lucira Health, Inc. (LHDX), Hartmann Hansgregory C., transaction 02/04/2021Lucira Health (LHDX) Chief Operating Officer Hansgregory C. Hartmann Form 4:…
Form 4: Lucira Health, Inc. (LHDX), Hartmann Hansgregory C., transaction 03/10/2021Lucira Health (LHDX) Chief Operating Officer Hansgregory C. Hartmann Form 4: 70,000-share…
Form 4: Lucira Health, Inc. (LHDX), Hartmann Hansgregory C., transaction 06/18/2021Lucira Health (LHDX) Chief Operating Officer Hansgregory C. Hartmann Form 4: 30,000-share…
Form 4: Lucira Health, Inc. (LHDX), Kashmolah Ghazi, transaction 09/30/2021Lucira Health (LHDX) Form 4: Chief Quality Officer Ghazi Kashmolah granted 197,240…
Form 4: Lucira Health, Inc. (LHDX), Lamond David, transaction 02/09/2021Lucira Health (LHDX) director David Lamond Form 4: preferred shares in Blue Devil Trust…
Form 4: Lucira Health, Inc. (LHDX), Lamond David, transaction 06/01/2022Lucira Health, Inc. [LHDX] Form 4: David Lamond, a Director, reports a stock option for…
Form 4: Lucira Health, Inc. (LHDX), McCauley Alison, transaction 06/01/2022Form 4, Lucira Health, Inc. [LHDX]: Alison McCauley, a Director, reports an option on…
Form 4: Lucira Health, Inc. (LHDX), McCauley Alison, transaction 12/17/2021Form 4: Lucira Health (LHDX) director Alison McCauley granted an option on 57,665 shares…
Form 4: Lucira Health, Inc. (LHDX), Mitra Debkishore, transaction 02/04/2021Lucira Health (LHDX) Form 4: director and Chief Technology Officer Debkishore Mitra…
Form 4: Lucira Health, Inc. (LHDX), Mitra Debkishore, transaction 03/10/2021Form 4: Lucira Health (LHDX) director and Chief Technology Officer Debkishore Mitra,…
Form 4: Lucira Health, Inc. (LHDX), Narido Richard Clavano, transaction 03/03/2023Lucira Health, Inc. [LHDX] Form 4: Richard Clavano Narido, Chief Financial Officer,…
Form 4: Lucira Health, Inc. (LHDX), Prashar Tamanna, transaction 02/04/2021Form 4 for Lucira Health (LHDX) Vice President Tamanna Prashar: option on 47,812 shares…
Form 4: Lucira Health, Inc. (LHDX), Prashar Tamanna, transaction 03/01/2022Form 4 for Lucira Health, Inc. [LHDX]: Tamanna Prashar, Vice President, reports…
Form 4: Lucira Health, Inc. (LHDX), Prashar Tamanna, transaction 03/10/2021Lucira Health (LHDX) Vice President Tamanna Prashar Form 4: Restricted Stock Unit award…
Form 4: Lucira Health, Inc. (LHDX), Prashar Tamanna, transaction 06/09/2021Form 4 for Lucira Health, Inc. [LHDX]: Tamanna Prashar, Vice President, reports…
Form 4: Lucira Health, Inc. (LHDX), Rogers Erica J., transaction 06/01/2022Lucira Health, Inc. [LHDX] Form 4 for Erica J. Rogers, a Director: stock option on 59,459…
Form 4: Lucira Health, Inc. (LHDX), Susan Lior, transaction 02/09/2021Lucira Health (LHDX) Form 4, director Lior Susan: Eclipse fund preferred stock and a…
Form 4: Lucira Health, Inc. (LHDX), Susan Lior, transaction 06/01/2022Form 4 for Lucira Health, Inc. [LHDX]: Lior Susan, marked Director and 10% Owner, reports…
Form 4: Lucira Health, Inc. (LHDX), Tablak Steve, transaction 06/01/2022Lucira Health, Inc. [LHDX] Form 4: Steve Tablak, a Director, reports a June 1, 2022…
Form 4: Lucira Health, Inc. (LHDX), Yen Tuff, transaction 02/09/2021Form 4: Lucira Health (LHDX) director Tuff Yen, Seraph entities' preferred stock and…
Form 4: Lucira Health, Inc. (LHDX), Yen Tuff, transaction 06/01/2022Form 4 filed for Tuff Yen, a Director of Lucira Health, Inc. [LHDX]: 59,459-share stock…
Form 4: Novavax Inc (NVAX), Glenn Gregory M, transaction 09/15/2021NOVAVAX INC [NVAX] Form 4: Gregory M. Glenn exercised options for 521 and 662 shares and…
Form 4: Novavax Inc (NVAX), Herrmann John A III, transaction 09/15/2021NOVAVAX INC [NVAX] Form 4: John A. Herrmann III exercised an option for 5,000 shares on…
Form 4: Novavax Inc (NVAX), King Rachel K., transaction 06/10/2022NOVAVAX INC [NVAX] Form 4: director Rachel K. King granted 3,100 RSUs and an option for…
Form 4: Novavax Inc (NVAX), King Rachel K., transaction 06/17/2022NOVAVAX INC [NVAX] Form 4: director Rachel K. King acquired 700 shares from vested RSUs…
Form 4: Ocugen, Inc. (OCGN), Castillo Kirsten, transaction 06/07/2022Ocugen, Inc. Form 4 for director Kirsten Castillo, June 7, 2022: option for 140,091…
Form 4: Ocugen, Inc. (OCGN), Fernandes Prabhavathi, transaction 06/07/2022Ocugen, Inc. Form 4 for director Prabhavathi Fernandes, June 7, 2022: option to buy…
Form 4: Ocugen, Inc. (OCGN), Kompella Uday, transaction 06/07/2022Ocugen, Inc. Form 4 for director Uday Kompella, June 7, 2022: grant of an option for…
Form 4: Ocugen, Inc. (OCGN), Kumar Ramesh, transaction 06/07/2022Ocugen, Inc. Form 4 for director Ramesh Kumar, June 7, 2022: a $2.49 option for 140,091…
Form 4: Ocugen, Inc. (OCGN), Kumar Ramesh, transaction 12/16/2021Ocugen, Inc. Form 4 for director Ramesh Kumar, December 16, 2021: a $5.02 option for…
Form 4: Ocugen, Inc. (OCGN), Musunuri Shankar, transaction 01/03/2022Ocugen, Inc. Form 4, Shankar Musunuri, January 3, 2022: 346,540 restricted stock units…
Form 4: Ocugen, Inc. (OCGN), Musunuri Shankar, transaction 12/16/2021Ocugen, Inc. Form 4, Shankar Musunuri, December 16, 2021: 115,000 shares sold at a $5.22…
Form 4: Ocugen, Inc. (OCGN), Potti Manish, transaction 12/16/2021Ocugen, Inc. Form 4 for director Manish Potti, December 16, 2021: options for 13,500 and…
Form 4: Ocugen, Inc. (OCGN), Subramanian Sanjay, transaction 01/03/2022Ocugen, Inc. Form 4, Chief Financial Officer Sanjay Subramanian, January 3, 2022: 125,534…
Form 4: Ocugen, Inc. (OCGN), Subramanian Sanjay, transaction 12/16/2021Ocugen, Inc. Form 4, Chief Financial Officer Sanjay Subramanian, December 16, 2021:…
Form 4: Ocugen, Inc. (OCGN), Whittington Marna C, transaction 06/07/2022Ocugen, Inc. Form 4 for director Marna Whittington, June 7, 2022: option on 140,091…
Form 4: Ocugen, Inc. (OCGN), Zhang Junge, transaction 06/07/2022Ocugen, Inc. Form 4 for director Junge Zhang, June 7, 2022: 140,091-share option at $2.49…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Asghar Najjam, transaction 03/16/2021Sorrento Therapeutics, Inc. Form 4, Chief Financial Officer Najjam Asghar, March 16,…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Asghar Najjam, transaction 11/12/2020Sorrento Therapeutics, Inc. Form 4, Chief Financial Officer Najjam Asghar, November 12,…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Czerepak Elizabeth, transaction 05/18/2022Sorrento Therapeutics, Inc. Form 4 for EVP & Chief Financial Officer Elizabeth Czerepak,…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Czerepak Elizabeth, transaction 11/18/2021Sorrento Therapeutics, Inc. Form 4 for director Elizabeth Czerepak, November 18, 2021:…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Followwill Dorman, transaction 06/15/2020Sorrento Therapeutics, Inc. Form 4 for director Dorman Followwill, June 15, 2020: options…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Followwill Dorman, transaction 08/30/2021Sorrento Therapeutics, Inc. Form 4 for director Dorman Followwill, August 30, 2021:…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Followwill Dorman, transaction 12/16/2020Sorrento Therapeutics, Inc. Form 4 for director Dorman Followwill: 1,000 shares acquired…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 04/12/2021Sorrento Therapeutics, Inc. Form 4 for director Kim Janda, April 12, 2021: 1,900 options…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 06/15/2020Sorrento Therapeutics, Inc. Form 4 for director Kim Janda, June 15, 2020: stock options…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 08/07/2020Sorrento Therapeutics, Inc. Form 4 for director Kim Janda, August 7, 2020: options on…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 08/30/2021Sorrento Therapeutics, Inc. Form 4 for director Kim Janda, August 30, 2021: 250,000-share…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 09/13/2021Sorrento Therapeutics, Inc. Form 4 for director Kim Janda, September 13, 2021: 8,000…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 09/27/2021Sorrento Therapeutics, Inc. Form 4 for director Kim Janda, September 27, 2021: 42,357…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 06/15/2020Sorrento Therapeutics, Inc. Form 4 for Henry Ji, June 15, 2020: stock options on…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 08/30/2021Sorrento Therapeutics, Inc. Form 4 for Henry Ji, August 30, 2021: option to buy 2,500,000…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 09/29/2021Sorrento Therapeutics, Inc. Form 4 for Henry Ji, September 29, 2021: non-qualified…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 10/16/2020Sorrento Therapeutics, Inc. Form 4 for Henry Ji, October 16, 2020: performance-based…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Lee Edgar, transaction 06/15/2020Sorrento Therapeutics, Inc. Form 4 for director Edgar Lee, June 15, 2020: 100,000-share…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Lemus David, transaction 06/15/2020Sorrento Therapeutics, Inc. Form 4 for director David Lemus, June 15, 2020: stock option…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Lemus David, transaction 08/30/2021Sorrento Therapeutics, Inc. Form 4 for director David Lemus, August 30, 2021: stock…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Reilly Tammy, transaction 05/18/2022Sorrento Therapeutics, Inc. Form 4 for director Tammy Reilly, May 18, 2022: option on…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Shah Jaisim, transaction 06/15/2020Sorrento Therapeutics, Inc. Form 4 for director Jaisim Shah, June 15, 2020: options to…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Shah Jaisim, transaction 08/30/2021Sorrento Therapeutics, Inc. Form 4 for director Jaisim Shah, August 30, 2021: option…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Shao Jiong, transaction 06/15/2020Sorrento Therapeutics, Inc. Form 4, Chief Financial Officer Jiong Shao, June 15, 2020:…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Smith Robin L, transaction 03/05/2020Sorrento Therapeutics, Inc. Form 4 for director Robin L. Smith, March 5, 2020: 40,000…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Smith Robin L, transaction 06/15/2020Sorrento Therapeutics, Inc. Form 4 for director Robin L. Smith, June 15, 2020: options on…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Smith Robin L, transaction 08/30/2021Sorrento Therapeutics, Inc. Form 4 for director Robin L. Smith, August 30, 2021: option…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Smith Robin L, transaction 09/03/2021Sorrento Therapeutics, Inc. Form 4 for director Robin L. Smith, September 3, 2021:…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Wu Yue Alexander, transaction 06/15/2020Sorrento Therapeutics, Inc. Form 4 for director Yue Alexander Wu, June 15, 2020: option…
Form 4: Sorrento Therapeutics, Inc. (SRNE), Wu Yue Alexander, transaction 08/30/2021Sorrento Therapeutics, Inc. Form 4 for director Yue Alexander Wu, August 30, 2021: option…
Form 4: Translate Bio, Inc. (TBIO), Barbier Ann, transaction 03/03/2020Translate Bio, Inc. Form 4, Chief Medical Officer Ann Barbier, March 3, 2020: option on…
Form 4: Translate Bio, Inc. (TBIO), Barbier Ann, transaction 03/09/2021Translate Bio, Inc. Form 4 for Chief Medical Officer Ann Barbier, March 9, 2021: option…
Form 4: Translate Bio, Inc. (TBIO), Beckman Daniella, transaction 06/16/2020Translate Bio, Inc. Form 4 for director Daniella Beckman, June 16, 2020: stock option to…
Form 4: Translate Bio, Inc. (TBIO), Beckman Daniella, transaction 06/16/2021Translate Bio, Inc. Form 4 for director Daniella Beckman, June 16, 2021: option grant on…
Form 4: Translate Bio, Inc. (TBIO), Beckman Daniella, transaction 09/14/2021Translate Bio, Inc. Form 4 for director Daniella Beckman, September 14, 2021: options…
Form 4: Translate Bio, Inc. (TBIO), Burgess Paul D., transaction 03/03/2020Translate Bio, Inc. Form 4 for Paul D. Burgess, March 3, 2020: 150,000-share option at…
Form 4: Translate Bio, Inc. (TBIO), Burgess Paul D., transaction 03/09/2021Translate Bio, Inc. Form 4 for officer Paul D. Burgess, March 9, 2021: option grant on…
Form 4: Translate Bio, Inc. (TBIO), Burgess Paul D., transaction 09/14/2021Translate Bio, Inc. Form 4 for officer Paul D. Burgess, September 14, 2021: 71,833 shares…
Form 4: Translate Bio, Inc. (TBIO), Demetri George, transaction 06/16/2020Translate Bio, Inc. Form 4 for director George Demetri, June 16, 2020: option on 18,900…
Form 4: Translate Bio, Inc. (TBIO), Demetri George, transaction 06/16/2021Translate Bio, Inc. Form 4 for director George Demetri, June 16, 2021: stock option on…
Form 4: Translate Bio, Inc. (TBIO), Demetri George, transaction 09/14/2021Translate Bio, Inc. Form 4 for director George Demetri, September 14, 2021: options…
Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 06/16/2020Translate Bio, Inc. Form 4 for director Jean-Francois Formela, June 16, 2020: option on…
Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 06/16/2021Translate Bio, Inc. Form 4 for director Jean-Francois Formela, June 16, 2021: right to…
Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 08/25/2020Translate Bio, Inc. Form 4 for director Jean-Francois Formela, August 25-27, 2020: sales…
Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 09/14/2021Translate Bio, Inc. Form 4 for director Jean-Francois Formela, September 14, 2021:…
Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 12/21/2020Translate Bio, Inc. Form 4 for director Jean-Francois Formela, December 21-22, 2020:…
Form 4: Translate Bio, Inc. (TBIO), Hughes Owen, transaction 06/16/2020Translate Bio, Inc. Form 4 for director Owen Hughes, June 16, 2020: 18,900-share option…
Form 4: Translate Bio, Inc. (TBIO), Hughes Owen, transaction 06/16/2021Translate Bio, Inc. Form 4 for director Owen Hughes, June 16, 2021: grant of an option to…
Form 4: Translate Bio, Inc. (TBIO), Hughes Owen, transaction 09/14/2021Translate Bio, Inc. Form 4 for director Owen Hughes, September 14, 2021: 29,860 shares…
Form 4: Translate Bio, Inc. (TBIO), Lynch Daniel, transaction 06/16/2020Translate Bio, Inc. Form 4 for director Daniel Lynch, June 16, 2020: grant of an option…
Form 4: Translate Bio, Inc. (TBIO), Meyer Robert J., transaction 06/16/2020Translate Bio, Inc. Form 4 for director Robert Meyer, M.D., June 16, 2020: stock option…
Form 4: Translate Bio, Inc. (TBIO), Meyer Robert J., transaction 06/16/2021Translate Bio, Inc. Form 4 for director Robert J. Meyer, June 16, 2021: stock option to…
Form 4: Translate Bio, Inc. (TBIO), Meyer Robert J., transaction 09/14/2021Translate Bio, Inc. Form 4 for director Robert J. Meyer, September 14, 2021: stock…
Form 4: Translate Bio, Inc. (TBIO), Plenge Robert M, transaction 06/16/2020Translate Bio, Inc. Form 4 for director Robert M. Plenge, June 16, 2020: option on 18,900…
Form 4: Translate Bio, Inc. (TBIO), Plenge Robert M, transaction 06/16/2021Translate Bio, Inc. Form 4 for director Robert M. Plenge, June 16, 2021: option covering…
Form 4: Translate Bio, Inc. (TBIO), Plenge Robert M, transaction 09/14/2021Translate Bio, Inc. Form 4 for director Robert M. Plenge, September 14, 2021: options…
Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 01/14/2021Translate Bio, Inc. Form 4 for director Ronald C. Renaud, Jr., January 14, 2021: options…
Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 03/03/2020Translate Bio, Inc. Form 4 for Ronald C. Renaud Jr., March 3, 2020: option on 525,000…
Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 03/09/2021Translate Bio, Inc. Form 4 for director Ronald C. Renaud, Jr., March 9, 2021: option on…
Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 04/07/2021Translate Bio, Inc. Form 4 for Chief Executive Officer Ronald C. Renaud, Jr., April 7,…
Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 09/14/2021Translate Bio, Inc. Form 4 for director Ronald C. Renaud, Jr., September 14, 2021: shares…
Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 11/16/2020Translate Bio, Inc. Form 4 for director Ronald C. Renaud, Jr., November 16, 2020: options…
Form 4: Translate Bio, Inc. (TBIO), Sanofi, transaction 09/14/2021Translate Bio, Inc. Form 4, September 14, 2021: Sanofi reports acquiring shares at $38 in…
Form 4: Translate Bio, Inc. (TBIO), Schroer John R., transaction 03/03/2020Translate Bio, Inc. Form 4, Chief Financial Officer John R. Schroer, March 3, 2020:…
Form 4: Translate Bio, Inc. (TBIO), Smith Brendan, transaction 04/19/2021Translate Bio, Inc. Form 4 for Chief Financial Officer Brendan Smith, April 19, 2021:…
Form 4: Translate Bio, Inc. (TBIO), Smith Brendan, transaction 09/14/2021Translate Bio, Inc. Form 4 for Chief Financial Officer Brendan Smith, September 14, 2021:…
Form 4: Translate Bio, Inc. (TBIO), Sutherland Everett Rand, transaction 03/22/2021Translate Bio, Inc. Form 4 for President Everett Rand Sutherland, March 22, 2021: option…
Form 4: Translate Bio, Inc. (TBIO), Sutherland Everett Rand, transaction 09/14/2021Translate Bio, Inc. Form 4 for President Everett Rand Sutherland, September 14, 2021:…
Form 4: Translate Bio, Inc. (TBIO), Wooster Richard, transaction 03/03/2020Translate Bio, Inc. Form 4, Chief Scientific Officer Richard Wooster, March 3, 2020:…
Form 4: Translate Bio, Inc. (TBIO), Wooster Richard, transaction 03/09/2021Translate Bio, Inc. Form 4 for Chief Scientific Officer Richard Wooster, March 9, 2021:…
Form 4: Vaxart, Inc. (VXRT), Cummings James F., transaction 03/28/2022Vaxart, Inc. Form 4: Chief Medical Officer James F. Cummings received 43,750 shares and a…
Form 4: Vaxart, Inc. (VXRT), Finney Michael J., transaction 06/08/2020Director Michael J. Finney's Vaxart, Inc. Form 4: a 65,700-share stock option at $2.39…
Form 4: Vaxart, Inc. (VXRT), Finney Michael J., transaction 06/16/2021Form 4: Vaxart, Inc. director Michael J. Finney acquired an option on 15,097 shares at…
Form 4: Vaxart, Inc. (VXRT), Finney Michael J., transaction 08/04/2022Vaxart, Inc. Form 4: director Michael J. Finney received 7,375 shares and an option for…
Form 4: Vaxart, Inc. (VXRT), Wheadon David E., transaction 06/16/2021Vaxart, Inc. Form 4: director David E. Wheadon received an option for 65,700 shares at…
Form 4: Vaxart, Inc. (VXRT), Wheadon David E., transaction 08/04/2022Form 4: Vaxart, Inc. director David E. Wheadon was granted 7,375 shares and an option on…
Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 01/10/2022Vaxart, Inc. Form 4: late report of a 01/10/2022 sale of 1,500 shares at $6.0101 owned by…
Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 06/08/2020Vaxart, Inc. Form 4: director Robert A. Yedid received an option on 65,700 shares at…
Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 06/11/2021Vaxart, Inc. Form 4: director Robert A. Yedid exercised an option for 18,240 shares and…
Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 06/16/2021Form 4: Vaxart, Inc. director Robert A. Yedid acquired a 15,097-share option at $7.79 on…
Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 08/04/2022Vaxart, Inc. Form 4: director Robert A. Yedid acquired 7,375 shares and a 44,224-share…
Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 08/19/2022Vaxart, Inc. Form 4: director Robert A. Yedid exercised options for 18,240 shares at…
Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 08/24/2022Vaxart, Inc. Form 4: director Robert A. Yedid gifted 18,240 shares to a registered…
Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 06/02/2022Joint Form 4 by ARCH Venture entities and Keith Crandell and Clinton Bybee on 06/02/2022…
Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 06/08/2022Joint Form 4 by ARCH Venture entities, Keith Crandell and Clinton Bybee on a 06/08/2022…
Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 08/12/2022Joint Form 4 by ARCH Venture entities, Keith Crandell and Clinton Bybee on August 2022…
Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 08/18/2022ARCH Venture entities, Keith Crandell and Clinton Bybee report an 08/18/2022 distribution…
Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 08/24/2022Joint Form 4 from ARCH Venture entities with Keith Crandell and Clinton Bybee on…
Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 08/30/2022ARCH Venture entities, Keith Crandell and Clinton Bybee jointly report 08/30/2022 and…
Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 09/02/2022Joint ARCH Venture Form 4 on 09/02/2022 and 09/06/2022 Vir Biotechnology distributions,…
Form 4: Vir Biotechnology, Inc. (VIR), Hanly Ann M., transaction 02/22/2022Form 4 for Vir Biotechnology Chief Technology Officer Ann M. Hanly: 53,500 RSUs and a…
Form 4: Vir Biotechnology, Inc. (VIR), Hatfield Jeffrey S., transaction 05/23/2022Form 4 for Vir Biotechnology director Jeffrey S. Hatfield: 6,405 shares and a…
Form 4: Vir Biotechnology, Inc. (VIR), Horn Howard, transaction 02/17/2022Vir Biotechnology Form 4: CFO Howard Horn's 2,393-share sale on 02/17/2022 to cover tax…
Form 4: Vir Biotechnology, Inc. (VIR), Horn Howard, transaction 02/22/2022Vir Biotechnology Form 4: CFO Howard Horn received 35,000 RSUs and a 50,000-share option…
Form 4: Vir Biotechnology, Inc. (VIR), More Robert J, transaction 05/23/2022Vir Biotechnology Form 4: director Robert J. More received 6,405 shares and an option on…
Form 4: Vir Biotechnology, Inc. (VIR), Nelsen Robert, transaction 12/20/2021Vir Biotechnology, Inc. Form 4 for director Robert Nelsen, December 20, 2021: ARCH…
Form 4: Vir Biotechnology, Inc. (VIR), Pang Phillip, transaction 02/22/2022Vir Biotechnology Form 4: Phillip Pang received 67,000 RSUs and a 64,000-share option at…
Form 4: Vir Biotechnology, Inc. (VIR), Perez Robert J, transaction 05/23/2022Robert J. Perez, Vir Biotechnology director, reports 6,405 shares and an option on 12,810…
Form 4: Vir Biotechnology, Inc. (VIR), Ramasastry Saira, transaction 05/23/2022Vir Biotechnology Form 4: director Saira Ramasastry received 6,405 shares and an option…
Form 4: Vir Biotechnology, Inc. (VIR), Rice Steven J., transaction 02/17/2022Form 4 for Vir Biotechnology Chief Administrative Officer Steven J. Rice: 1,942 shares…
Form 4: Vir Biotechnology, Inc. (VIR), Rice Steven J., transaction 02/22/2022Vir Biotechnology Form 4: Steven J. Rice received 20,000 RSUs and a 40,000-share option…
Form 4: Vir Biotechnology, Inc. (VIR), Sato Vicki L, transaction 12/20/2021Vir Biotechnology, Inc. Form 4 for director Vicki L. Sato, December 20, 2021: common…
Form 4: Vir Biotechnology, Inc. (VIR), Scangos George A, transaction 02/17/2022Vir Biotechnology Form 4: President and CEO George A. Scangos sold 10,024 and 17,726…
Form 4: Vir Biotechnology, Inc. (VIR), Scangos George A, transaction 03/10/2022Vir Biotechnology Form 4: CEO George A. Scangos received 111,000 RSUs and a 222,000-share…
Form 4: Vir Biotechnology, Inc. (VIR), Sigal Charles Elliott, transaction 05/23/2022Vir Biotechnology Form 4 dated 05/23/2022: director Charles Elliott Sigal acquired 6,405…
Form 4: Vir Biotechnology, Inc. (VIR), Virgin Herbert, transaction 02/17/2022Vir Biotechnology insider filing: Herbert Virgin's 2,293-share automatic sale on…
Form 4: Vir Biotechnology, Inc. (VIR), Virgin Herbert, transaction 02/22/2022Herbert Virgin Form 4 for Vir Biotechnology: 70,000 RSUs, a 70,000-share option grant and…
Form 4: Vir Biotechnology, Inc. (VIR), Virgin Herbert, transaction 03/10/2022Vir Biotechnology Form 4: Herbert Virgin exercised a fully vested option for 9,000 shares…
Form 6-K — CureVac N.V., data from Phase 2b/3 of First-Generation COVID-19 Vaccine, June 30, 2021CureVac N.V. Form 6-K (June 30, 2021), File No. 001-39446: press release on final Phase…
Form 6-K — CureVac N.V.: acquisition of Frame Cancer Therapeutics (June 8, 2022)CureVac N.V. Form 6-K (June 8, 2022), File No. 001-39446: press release on the…
Form 6-K — CureVac N.V.: appointment of Dr. Malte Greune as Chief Operating Officer (June 30, 2021)CureVac N.V. Form 6-K (June 30, 2021), File No. 001-39446: press release naming Dr. Malte…
Form 6-K — CureVac N.V.: Chief Development Officer Klaus Edvardsen will leave the Company (June 8, 2022)CureVac N.V. Form 6-K (June 8, 2022), File No. 001-39446: press release on the Chief…
Form 6-K — CureVac N.V.: contract with the German federal government to supply mRNA vaccines (April 11, 2022)CureVac N.V. Form 6-K (Apr. 11, 2022), File No. 001-39446: press release on a German…
Form 6-K — CureVac N.V.: convened the annual general meeting of shareholders for June 22, 2022 (June 1, 2022)CureVac N.V. Form 6-K (June 1, 2022), File No. 001-39446: convening of the annual general…
Form 6-K — CureVac N.V.: data from the Phase 1 clinical trial of CV8102 (November 10, 2021)CureVac N.V. Form 6-K (Nov. 10, 2021), File No. 001-39446: press release on…
Form 6-K — CureVac N.V.: departure of the Company's Chief Technology Officer (January 17, 2022)CureVac N.V. Form 6-K (Jan. 17, 2022), File No. 001-39446: press release on the departure…
Form 6-K — CureVac N.V.: dievini, KfW and Dietmar Hopp amended the KfW dievini Shareholders' Agreement (2022)CureVac N.V. Form 6-K (Jan. 13, 2022), File No. 001-39446: filing of a second amendment…
Form 6-K — CureVac N.V.: dosed the first participant, Phase 1 seasonal influenza vaccine candidate (2022)CureVac N.V. Form 6-K (Feb. 10, 2022), File No. 001-39446: press release on first…
Form 6-K — CureVac N.V.: Dr. Ingmar Hoerr withdrew his candidacy for the Supervisory Board (June 23, 2021)CureVac N.V. Form 6-K (June 23, 2021), File No. 001-39446: press release on Supervisory…
Form 6-K — CureVac N.V.: financial results for the first quarter of 2022 (May 25, 2022)CureVac N.V. Form 6-K (May 25, 2022), File No. 001-39446: press release on first quarter…
Form 6-K — CureVac N.V.: financial results for the fourth quarter and full-year of 2021 (April 28, 2022)CureVac N.V. Form 6-K (Apr. 28, 2022), File No. 001-39446: press release on fourth…
Form 6-K — CureVac N.V.: financial results for the second quarter and first half of 2021 (August 16, 2021)CureVac N.V. Form 6-K (Aug. 16, 2021), File No. 001-39446: press release on…
Form 6-K — CureVac N.V.: financial results for the second quarter and first half of 2022 (August 18, 2022)CureVac N.V. Form 6-K (Aug. 18, 2022), File No. 001-39446: press release on second…
Form 6-K — CureVac N.V.: financial results for the third quarter and nine months of 2021 (November 18, 2021)CureVac N.V. Form 6-K (Nov. 18, 2021), File No. 001-39446: press release on third quarter…
Form 6-K — CureVac N.V.: financial results for the third quarter and nine months of 2022 (November 17, 2022)CureVac N.V. Form 6-K (Nov. 17, 2022), File No. 001-39446: press release on third quarter…
Form 6-K — CureVac N.V.: first participant was dosed in a Phase 1 study of CV2CoV, with GSK (March 30, 2022)CureVac N.V. Form 6-K (Mar. 30, 2022), File No. 001-39446: press release on first…
Form 6-K — CureVac N.V.: formation of CureVac RNA Printer GmbH, Markus Bergmann General Manager (2022)CureVac N.V. Form 6-K (Mar. 1, 2022), File No. 001-39446: press release on formation of…
Form 6-K — CureVac N.V.: HERALD study data of CVnCoV in Preprints with The Lancet (August 31, 2021)CureVac N.V. Form 6-K (Aug. 31, 2021), File No. 001-39446: press release on HERALD…
Form 6-K — CureVac N.V.: Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021CureVac N.V. Form 6-K (Jan. 3, 2022), File No. 001-39446: furnishes unaudited interim…
Form 6-K — CureVac N.V.: Interim Condensed Consolidated Financial Statements as of June 30, 2022CureVac N.V. Form 6-K (Aug. 18, 2022), File No. 001-39446: furnishes interim financial…